Evidence map›Paper›PMID 42859673›Full record

ReviewDrug design, development and therapy2026

From Mechanistic Evidence to Clinical Translation: A Narrative Review of Chinese Herbal Medicine for Insomnia.

Ximing Li, Hanying Xu, Ying Zhang, Jing Lu, Yibin Zhang, Lin Zhang, Lan Yu, Hongmei Nan

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ximing Li *College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, 130117, People's Republic of China.
Hanying Xu *Department of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130021, People's Republic of China.ORCID 0000-0003-1380-7260
Ying ZhangDepartment of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130021, People's Republic of China.ORCID 0009-0009-7036-0291
Jing LuResearch Center of Traditional Chinese Medicine, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130021, People's Republic of China.
Yibin ZhangDepartment of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130021, People's Republic of China.
Lin ZhangDepartment of Neurology, Jilin City Traditional Chinese Medicine Hospital, Jilin, Jilin, 132000, People's Republic of China.
Lan YuDepartment of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130021, People's Republic of China.
Hongmei NanDepartment of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130021, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insomnia is one of the most common sleep disorders and a major public health problem worldwide. Chinese herbal medicine (CHM) is widely used as a complementary and alternative approach for chronic insomnia. Clinical studies have reported preliminary evidence of benefit for Chinese herbal formulas, whereas mechanistic research has examined single herbs, extracts, active constituents, and compound formulas using multi-omics analysis, network pharmacology, molecular prediction, and experimental validation. However, clinical studies are typically small and of inconsistent methodological quality, with limited long-term follow-up, while mechanistic evidence remains fragmented and lacks systematic integration and translational validation. These limitations restrict the development of CHM interventions from experimental evidence to clinically testable interventions for insomnia. This narrative review evaluates existing research across five translational dimensions, namely chemical characterization and preparation quality, exposure and pharmacodynamic evidence, mechanism and target validation, sleep-related clinical endpoints, and safety. It aims to clarify the current state of research on CHM interventions for insomnia and to identify key limitations and priorities for future research. Most available evidence comes from preclinical studies, which suggest that CHM may influence sleep-related processes through γ-aminobutyric acid (GABA) and serotonergic signaling, the hypothalamic-pituitary-adrenal (HPA) axis, neuroinflammation, oxidative stress, apoptosis-autophagy balance, and the brain-gut-microbiota axis. Much of this evidence reflects changes in biochemical markers or pathway activity, while only a few studies directly test target function. Clinical studies provide preliminary evidence of short-term improvements in subjective sleep outcomes. However, clinical translation remains limited by insufficient evidence for objective sleep improvement and long-term efficacy and safety. Future work should carry a few well-characterized interventions through the full evidence chain, prioritizing standardized preparations, exposure and pharmacodynamic assessment, objective sleep endpoints, long-term follow-up, and safety.

Indexed as

Drugs, Chinese HerbalSleep Initiation and Maintenance DisordersAnimalsHumansTranslational Research, BiomedicalDrugs, Chinese Herbalactive constituentsChinese herbal medicineclinical evidenceherbal formulasinsomnianeurobiological mechanisms

Identifiers

PMID42859673
PMCPMC13653551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.